Keane's Corner VL

Review of Recent Prostate Cancer Trial Results - January 2015

Details
Review of Recent Prostate Cancer Trial Results - January 2015 Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA SEE RELATED CONTENT : Duration of androgen suppression before radiotherapy for localized prostate cancer: Radiation Therapy Oncology Group randomized clinical trial 9910 - Abstract BIOGRAPHY Thomas E. Keane, M...

Review of Highlights from 2014

Details
Review of Highlights from 2014 Xofigo® Xtandi® Zytiga® CHAARTED study PD-L1 inhibitor in metastatic bladder cancer Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as prin...

The Role of GDF-15 Expression and Vitamin D in the Prostate

Details
Reduced Expression of GDF-15 is Associated with Atrophic Inflammatory Lesions of the Prostate Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or...

Practical Guide to Radium-223 in mCRPC

Details
Practical Guide to Radium-223 in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) This video blog by Dr. Keane discusses a recently published review article on the background of Radium-223. Radium-223 has demonstrated survival benefits in symptomatic men with prostate cancer, while managing the pain associated with bone metastases. Thomas E. Keane, MD Professor and Chairman...

Practical Guide to the use of Abiraterone in CRPC

Details
Practical Guide to the use of Abiraterone in Castration-resistant Prostate Cancer (CRPC) Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA Click HERE to read the abstract BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served a...

Practical Guide to Immunotherapy in CRPC

Details
Review of Canadian Journal of Urology Supplement from April 2014 - Practical Guide to Immunotherapy in CRPC: The Use of Sipuleucel-T Immunotherapy Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA Click HERE to read the abstract BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and...

Keane's Commentary - Results from ERSPC at 13 Years of Follow-up

Details
Commentary - Screening and Prostate Cancer Mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 Years of Follow-up published in The Lancet Thomas E. Keane, MD Click HERE to read the abstract Click HERE to listen to one of the authors, Fritz H. Schröder MD, discuss this review

Most PCa Specialists Believe AS in Low-risk PCa is Effective and Underused

Details
Most PCa Specialists Believe AS in Low-risk PCa is Effective and Underused - Perspectives from the Editor-in-Chief (August 2014) Thomas E. Keane, MD Related Content : Click HERE to read the abstract for Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: Results from a national survey of radiation oncologists and urologists

Rates of Mgmt of Low-risk PCa with Observation Varies Widely Across Urologists and Rad Oncs

Details
Rates of Management of Low-risk Prostate Cancer with Observation Varies Widely Across Urologists and Radiation Oncologists - Perspectives from the Editor-in-Chief (August 2014) Thomas E. Keane, MD Related Content : Click HERE to read the abstract for Physician variation in management of low-risk prostate cancer: A population-based cohort study

Men with PCa and Recent Dx of Depression Less Likely to Undergo Definitive Tx & Experience Worse OS

Details
Men with Prostate Cancer and Recent Diagnosis of Depression are Less Likely to Undergo Definitive Treatment and Experience Worse Overall Survival - Perspectives from the Editor-in-Chief (July 2014) Thomas E. Keane, MD Related Content : Click HERE to read the abstract for Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer Click HERE to watch...